Published in Biotech Business Week, August 9th, 2004
ATLAS is the first clinical trial using Boston Scientific's new Liberte coronary stent as a platform for its paclitaxel-eluting coronary stent system. Taxus Liberte will be the next generation to Boston Scientific's current paclitaxel-eluting stent system, Taxus Express2.
The Liberte stent, which has been designed to further enhance deliverability and conformability, particularly in challenging lesions, is currently available in international markets in a bare metal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.